-
UNAIDS recently released its 2007 estimates of the HIV epidemic worldwide, and included these essential findings in its 2007 AIDS Epidemic Update, which is available on the UNAIDS Web site at www.unaids.org:
-
The latest data by UNAIDS of Geneva, Switzerland, show that the global HIV pandemic has leveled off, with an estimated 33.2 million people infected, 2.5 million new infections last year, and 2.1 million AIDS deaths in 2007.
-
On Nov. 9, 2007, the FDA approved a new half-strength Kaletra tablet formulation. Each film-coated tablet contains 100 mg lopinavir and 25 mg ritonavir.
-
One of the challenges in targeting Latinos in the United States for HIV prevention messages has been the diversity of this ethnic group, both culturally and geographically.
-
-
One of the major problems the HIV prevention field has had is translating successful research into success in the real world. This challenge is even more of a hurdle when it comes to sending successful programs designed in the United States to sub-Saharan African and other developing world settings.
-
Progress toward an effective HIV vaccine has encountered a major roadblock with the cessation of a HIV vaccine clinical trial sponsored by Merck & Co. Meanwhile, the need for an effective vaccine continues to grow: The number of new infections in 2006 rose to 4.3 million around the globe, 400,000 more than in 2004.
-
Officials at the District of Columbia Department of Health (DOH) are retooling the city's condom distribution program after meeting public resistance to its customized condoms.
-
Researchers have launched a clinical safety trial of VivaGel (SPL7013), a topical vaginal microbicide, for potential use in preventing the sexual transmission of HIV.
-
New, unpublished research supports the idea that HIV prevention programs on the Internet could have a positive impact on behavioral change.
